FSTL3 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O95633 |
---|---|
Clone Names | 100318038 |
Gene ID | 10272 |
---|---|
Other Names | Follistatin-related protein 3, Follistatin-like protein 3, Follistatin-related gene protein, FSTL3, FLRG |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | FSTL3 |
---|---|
Synonyms | FLRG |
Function | Isoform 1 or the secreted form is a binding and antagonizing protein for members of the TGF-beta family, such us activin, BMP2 and MSTN. Inhibits activin A-, activin B-, BMP2- and MSDT-induced cellular signaling; more effective on activin A than on activin B. Involved in bone formation; inhibits osteoclast differentiationc. Involved in hematopoiesis; involved in differentiation of hemopoietic progenitor cells, increases hematopoietic cell adhesion to fibronectin and seems to contribute to the adhesion of hematopoietic precursor cells to the bone marrow stroma. Isoform 2 or the nuclear form is probably involved in transcriptional regulation via interaction with MLLT10. |
Cellular Location | [Isoform 1]: Secreted. |
Tissue Location | Expressed in a wide range of tissues. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Follistatin-like 3 is a secreted glycoprotein of thefollistatin-module-protein family. It may have a role inleukemogenesis.
References
Miron, P., et al. Prenat. Diagn. 30(3):224-228(2010)Thadhani, R., et al. Diabetes Care 33(3):664-669(2010)Bloise, E., et al. BMC Cancer 9, 320 (2009) :Stamler, R., et al. J. Biol. Chem. 283(47):32831-32838(2008)Lara-Pezzi, E., et al. Endocrinology 149(11):5822-5827(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.